Effects of miR-138 on invasion of brain glioma cells through targeting Sema4C

doi:10.3760/cma.j.issn.1673-422X.2018.03.003

Abstract

Abstract: ObjectiveTo explore the effects and mechanism of microRNA-138 (miR-138) on brain glioma cells invasion and migration. MethodsThe expression of miR138 was detected by real time quantitative polymerase chain reaction (qRT-PCR) in 60 cases of glioma tissues and paracarcinoma tissues, and the relationship between miR138 expression and glioma grading was analyzed. Human glioma cells line U87 and U251 were transfected with miR138 mimic and negative control (miR-NC). The expression of miR138 was detected by qRTPCR. The migration and invasion abilities were tested by Transwell assay, and the expression of semaphoring 4C (Sema4C) protein was tested by Western blotting. ResultsThe expression level of miR-138 in glioma tissues (2.46±1.07) was significantly lower than that in normal brain tissues (4.83±1.16, t=-11.631, P＜0.001), and miR138 expression was negatively correlated with tumor grade (r=-0.563, P=0.001). The expression level of miR138 in cells was significantly higher after being transfected with miR-138 mimic (U251: 3.96±0.16; U87: 4.43±0.96) than miR-NC (U251: 2.32±0.36; U87: 2.58±0.62, t=7.253, P＜0.001; t=8.872, P＜0.001). The ability of invasion and migration were lower after being transfected with miR-138 mimic (U251: 89±9; U87: 95±10) than miR-NC (U251: 206±15; U87: 240±20, t=36.629, P＜0.001; t=35.521, P＜0.001). The expression of Sema4C protein was lower after being transfected with miR-138 mimic (U251: 0.41±0.06; U87: 0.36±0.03) than miRNC (U251: 1.01±0.08; U87: 1.03±0.13, t=-32.862, P＜0.001; t=-27.512, P＜0.001). ConclusionThe upregulated expression of miR138 can suppress glioma cells migration and invasion, which might be related to the negative regulation expression of Sema4C protein.

Key words: Glioma, Neoplasm invasiveness, Neoplasm metastasis, microRNA-138, Semaphoring 4C

Li Huibing, Yao Juan. Effects of miR-138 on invasion of brain glioma cells through targeting Sema4C[J]. Journal of International Oncology, 2018, 45(3): 139-142.

References

［1］尤永平, 刘宁, 傅震. 中国胶质瘤规范化治疗现状［J］. 中国肿瘤外科杂志, 2012, 4(3): 129-131. DOI: 10.3969/j.issn.1674-4136.2012.03.001. ［2］中华医学会神经外科分会肿瘤专业组. 中国中枢神经系统恶性胶质瘤诊断和治疗共识(简化版)［J］. 中华医学杂志, 2009, 89(43): 3028-3030. DOI: 10.3760/cma.j.issn.0376-2491.2009.43.002. ［3］ Giordano S, Columbano A. MicroRNAs: new tools for diagnosis,prognosis, and therapy in hepatocellular carcinoma?［J］. Hepatology, 2013, 57(2): 840-847. DOI: 10.1002/hep.26095. ［4］董方, 薛金才, 王小虎. 恶性脑胶质瘤的综合治疗［J］. 国际肿瘤学杂志, 2014, 41(11): 816-820. DOI: 10.3760/cma.j.issn.1673-422X.2014.11.006. ［5］ Yao Y, Ma Y, Xue Y, et al. Knockdown of long noncoding RNA XIST exerts tumorsuppressive functions in human glioblastoma stem cells by upregulating miR-152［J］. Cancer Lett, 2015, 359(1): 75-86. DOI: 10.1016/j.canlet.2014.12.051. ［6］英舟, 万义增, 陈素贤. MiR-138靶向调控PDK1基因抑制人结肠癌SW620细胞侵袭［J］. 肿瘤防治研究, 2016, 43(5): 340-344. DOI: 10.3971/j.issn.1000-8578.2016.05.005. ［7］陈陵, 梁光萍, 邹利全, 等. MiR138对人胃腺癌细胞SGC7901增殖的影响［J］. 中国肿瘤临床, 2011, 38(13): 755-758. DOI: 10.3969/j.issn.1000-8179.2011.13.002. ［8］ Chen Y, Zeng J, Guan J, et al. Reformatted computed tomographic evaluation of the thoracic pedicle in a Chinese population for the surgical application of transpedicular screw placement［J］. Surg Radiol Anat, 2010, 32(5): 463-468. DOI: 10.1007/s00276-0090592-x. ［9］王震, 刘楠, 刘辉, 等. MicroRNA-138在胶质瘤中的表达及其功能研究［J］. 转化医学电子杂志, 2017, 4(7): 48-51. ［10］ KongBeltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation［J］. Cancer Cell, 2004, 6(1): 75-84. DOI: 10.1016/j.ccr.2004.06.013. ［11］陈颖, 张磊, 刘文欣, 等. Semaphorin4C在乳腺癌子宫内膜癌及前列腺癌中的表达及意义［J］. 中国肿瘤临床, 2010, 37(9): 507-511. DOI: 10.3969/j.issn.1000-8179.2010.09.007. ［12］ Li JF, Wang Q, Wen R, et al. MiR138 inhibits cell proliferation and reverses epithelialmesenchymal transition in nonsmall cell lung cancer cells by targeting GIT1 and SEMA4C［J］. J Cell Mol Med, 2015, 19(12): 2793-2805. DOI: 10.1111/jcmm.12666.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[3]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[6]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[7]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[8]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[9]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[10]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[11]	Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361.
[12]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[13]	Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607.
[14]	Wang Bin, Zhou Jiangyun, Liu Xi. Analysis of the clinical value of different radiotherapy schemes in patients with advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(8): 484-488.
[15]	Jiang Mengting, Wang Jiachun, Zong Jing. Effects of NFAT5 inhibition on proliferation, invasion, migration and apoptosis of lung adenocarcinoma cells [J]. Journal of International Oncology, 2021, 48(6): 321-327.